ImmunityBio said in Culver City, California, on November 9 that ANKTIVA combined with BCG met the primary efficacy endpoint in Cohort A of its randomized QUILT-2.005 bladder cancer trial. The company reported a statistically significant improvement over BCG alone in patients with carcinoma in situ, with or without papillary tumors, but did not release the numerical results needed to judge the size of that benefit.
The company’s announcement concerns high-grade non-muscle-invasive bladder cancer in patients described as BCG-naive, an earlier treatment setting than the BCG-unresponsive population for which ANKTIVA is already approved. Non-muscle-invasive means the cancer has not invaded the bladder’s muscle layer. ANKTIVA and BCG are given directly into the bladder, rather than as systemic chemotherapy.
The study compares the combination with BCG alone and is open-label, meaning the treatment assignment is not concealed. The trial registry identifies Cohort A’s primary outcome as complete response rate at six months and lists a separate disease-free-survival outcome for Cohort B. Monday’s reported primary-endpoint success is for Cohort A, not a claim that every outcome in both groups has been met.
ImmunityBio said enrollment was completed in February 2026 with 370 randomized patients and that the trial involved more than 75 sites. It did not give a separate Cohort A patient count in the release. The registry currently lists 369 actual participants, a small enrollment discrepancy the announcement does not explain. Database lock, the point at which the analysis data were finalized, occurred October 20, according to the company.
The significance is the possibility of adding ANKTIVA earlier in treatment, when patients are receiving BCG-based therapy rather than after their disease has failed to respond to it. A randomized comparison with BCG alone is intended to test whether the additional drug improves outcomes beyond that existing treatment. However, the release does not establish how many more patients responded, how durable any advantage is or whether bladder removal or survival outcomes improved.
ImmunityBio said median duration of response had not yet been reached with the combination and that patient-reported quality of life was maintained. A median that has not been reached is not a promise of permanent response. Without the follow-up duration and the underlying response data, readers cannot determine from the announcement how long the typical benefit will last.
The company reported no treatment-related deaths and said the most common treatment-emergent and treatment-related adverse events were consistent with those seen with BCG alone. It did not provide serious-adverse-event counts or detailed comparative safety tables. Those statements do not mean treatment has no risks, or that uncommon and later side effects have been ruled out.
A supplemental Biologics License Application remains planned for submission to the U.S. Food and Drug Administration by the end of 2026. That is a filing target, not a completed submission or an approval for BCG-naive disease. The company said further study details would be presented at an upcoming medical congress but did not identify the meeting or a presentation date.
The missing information includes response rates, the absolute or relative treatment effect, the p-value, confidence intervals, length of follow-up and detailed serious side effects. Those figures will be needed to assess the strength and practical importance of the result. For now, Monday’s news is a company-reported trial milestone and a planned regulatory filing, not a cure or proof that clinical practice should change.
JBizNews Desk | Culver City, California
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
